Heartbeats can now be measured without placing sensors on the body, thanks to a new technology developed in Japan. Researchers at the Kyoto University Center of Innovation, together with Panasonic Corp., have come up with a way to measure heartbeats remotely, in real time, and under controlled conditions with as much accuracy as electrocardiographs.

January 26, 2016 — In a breakthrough that could change the future of pacemakers, Technion-Israel Institute of Technology researchers have used mechanical stimulation to “train” cardiac cells to beat at a given rate.

January 26, 2016 — Fujifilm SonoSite Inc. announced CE mark and U.S. Food and Drug Administration (FDA) 510(k) clearance for its new portable ultrasound system, the SonoSite Edge II. Designed with emergency medicine and critical care applications in mind, the Edge II features new transducer technology that delivers a better imaging experience for the most rugged environments.

Now, medical technology purchasers and users have an instant online forum to rate and review technologies they are using, with Rate This Model, the newest enhancement to the ECRI Institute’s SELECTplus capital decision support solutions suite.

St. Jude Medical is recalling the Optisure implantable cardioverter defibrillator (ICD) leads due to a manufacturing error that may have caused damage to the insulation layer of one of the shock coils. Depending on device programming and the depth of the cut, this could result in the inability of the defibrillator to deliver electrical therapy to the patient. The use of affected products may cause serious adverse health consequences, including patient injury or death. 

The suspension of the medical device excise tax will have positive consequences for the U.S. medical device market over the next few years, says an analyst with research and consulting firm GlobalData.

New recommendations from the American College of Cardiology (ACC) and the American College of Radiology (ACR) have established appropriate use of diagnostic imaging for patients with chest pain, one of the most common reasons for emergency department visits.

3-D Echo Workshop at Echo 2016

ttend the Wednesday afternoon workshop and you will receive a time-limited, fully functional, up-loadable version of QLAB as well as important TEE and TTE volumes. Workshop features:

  • WORKSHOP 3DQ: Analysis of Aortic Valve Morphology, 
    Aortic Root Morphology and Function
  • WORKSHOP 3DQ: Analysis of Mitral Valve Morphology and Function
  • WORKSHOP 3DQ: Calculating EF and LV Mass
  • And the opportunity for Q&A
This illustrates how volanesorsen works to prevent the formation of apoC-III protein. Familial chylomicronemia syndrome (FCS) is a rare, genetic disease characterized by mutations in genes affecting the production or functionality of lipoprotein lipase (LPL).
Consistent with previous clinical observations with this drug in non-FCS HTG patients, volanesorsen produced significant, rapid and prolonged reductions in mean fasting plasma apoC-III (-81%) and TG (-69%) levels. Familial chylomicronemia syndrome (FCS) is a rare, genetic disease characterized by mutations in genes affecting the production or functionality of lipoprotein lipase (LPL).
volanesorsen. Familial chylomicronemia syndrome (FCS) is a rare, genetic disease characterized by mutations in genes affecting the production or functionality of lipoprotein lipase (LPL).

Familial chylomicronemia syndrome (FCS) is a rare, genetic disease characterized by mutations in genes affecting the production or functionality of lipoprotein lipase (LPL), an enzyme necessary for the metabolism of triglycerides (TG). People living with FCS can present with severe hypertriglyceridemia (HTG) and an elevated risk of TG-induced pancreatitis. Apolipoprotein C-III (apoC-III), a 79 amino acid glycoprotein that is synthesized principally in the liver, is a key regulator of serum TG.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now